Babińska Anna, Pęksa Rafał, Wiśniewski Piotr, Sworczak Krzysztof
Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.
Department of Pathology, Medical University of Gdansk, Gdansk, Poland.
Arch Med Sci. 2019 Sep;15(5):1254-1260. doi: 10.5114/aoms.2018.76142. Epub 2018 Jun 1.
The role of adipokines in neoplasms not related to obesity is unclear. The presence of adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2) as well as the leptin receptor (Ob-R) has been recognized in human adrenal tumors. The authors of the present study were the first to compare the expression of these receptors in histopathologically distinct adrenal tumors.
The study encompassed tissue specimens of 128 patients with adrenal tumors (28 adrenal cortical adenomas (CA), 35 cortical nodular hyperplasia tumors (CNH), 20 cortical carcinomas (CC), 40 pheochromocytomas (PHEO), 5 malignant pheochromocytomas (PHEOM)) operated on at a single clinical center. The expression of the adiponectin receptors AdipoR1 and AdipoR2 as well as the leptin receptor Ob-R was assessed by immunohistochemistry. The results were correlated with body mass index (BMI) and gender of the patients.
AdipoR1 expression was significantly higher in cortical cancers ( < 0.001) and pheochromocytomas ( < 0.001) as compared to benign cortical tumors. AdipoR2 expression was significantly higher in cortical carcinomas as compared to cortical adenomas and hyperplasia tumors ( = 0.01), and also significantly higher in pheochromocytomas in comparison to adrenocortical cancers ( = 0.004). Leptin receptor expression was absent or minimal in half of nodular hyperplasia tumors and adrenal cortex adenomas. This receptor's expression was significantly higher in adrenocortical cancers ( = 0.038). In pheochromocytomas this receptor was expressed more abundantly than in adrenocortical cancers ( = 0.004).
These novel findings suggest that adiponectin and leptin receptors could play a regulatory role in human adrenal neoplasms.
脂肪因子在与肥胖无关的肿瘤中的作用尚不清楚。在人类肾上腺肿瘤中已发现脂联素受体1和2（AdipoR1和AdipoR2）以及瘦素受体（Ob-R）的存在。本研究的作者首次比较了这些受体在组织病理学上不同的肾上腺肿瘤中的表达。
本研究纳入了在单一临床中心接受手术的128例肾上腺肿瘤患者的组织标本（28例肾上腺皮质腺瘤（CA）、35例皮质结节性增生肿瘤（CNH）、20例皮质癌（CC）、40例嗜铬细胞瘤（PHEO）、5例恶性嗜铬细胞瘤（PHEOM））。通过免疫组织化学评估脂联素受体AdipoR1和AdipoR2以及瘦素受体Ob-R的表达。结果与患者的体重指数（BMI）和性别相关。
与良性皮质肿瘤相比，AdipoR1在皮质癌（<0.001）和嗜铬细胞瘤（<0.001）中的表达显著更高。与皮质腺瘤和增生肿瘤相比，AdipoR2在皮质癌中的表达显著更高（=0.01），与肾上腺皮质癌相比，在嗜铬细胞瘤中的表达也显著更高（=0.004）。在一半的结节性增生肿瘤和肾上腺皮质腺瘤中，瘦素受体表达缺失或极少。该受体在肾上腺皮质癌中的表达显著更高（=0.038）。在嗜铬细胞瘤中，该受体的表达比肾上腺皮质癌中更丰富（=0.004）。
这些新发现表明脂联素和瘦素受体可能在人类肾上腺肿瘤中发挥调节作用。
